Cassava Sciences reported 2.6M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.


Interest Expense On Debt Change Date
Abbott USD 50M 1000K Jun/2025
Amgen USD 694M 29M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
Cassava Sciences 2.6M 301K Sep/2024
Eisai 916M 174M Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Geron USD 8.52M 233K Jun/2025
J&J USD 128M 9M Mar/2025
Merck USD 305M 8M Jun/2025
Novartis USD 289M 19M Jun/2025
Pfizer USD 654M 0 Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024